Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

10x Genomics (TXG) Other Gross PP&E Adjustments (2018 - 2025)

10x Genomics (TXG) has disclosed Other Gross PP&E Adjustments for 8 consecutive years, with $295.3 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments rose 1.3% to $295.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $295.3 million through Dec 2025, up 1.3% year-over-year, with the annual reading at $295.3 million for FY2025, 1.3% up from the prior year.
  • Other Gross PP&E Adjustments hit $295.3 million in Q4 2025 for 10x Genomics, down from $314.7 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $323.8 million in Q3 2024 to a low of -$75.7 million in Q1 2022.
  • Historically, Other Gross PP&E Adjustments has averaged $191.7 million across 5 years, with a median of $292.5 million in 2023.
  • Biggest five-year swings in Other Gross PP&E Adjustments: tumbled 190.35% in 2022 and later skyrocketed 535.6% in 2023.
  • Year by year, Other Gross PP&E Adjustments stood at $145.3 million in 2021, then soared by 83.97% to $267.4 million in 2022, then increased by 9.72% to $293.4 million in 2023, then decreased by 0.62% to $291.6 million in 2024, then grew by 1.3% to $295.3 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for TXG at $295.3 million in Q4 2025, $314.7 million in Q3 2025, and $316.8 million in Q2 2025.